John Boozman
Tickers in This Filing
Price Movement Since Trade
How each stock has moved from the trade date to the most recent close.
Suspicious Timing Detected
3 flagsRep. John Boozman sold $1,001 - $15,000 in $JNJ on 2026-03-19, 8 days before HR8143 was introduced, which mandates Medicare Part D plans to include generic and biosimilar drugs.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| SELL | $JNJ | Johnson & Johnson | $1K-$15K | $237.60 | $228.17 | -4.0% | Mar 19, 2026 |
| SELL | $BBEU | JPMORGAN BETABULDR EUROP ETF(ETF) | $15K-$50K | $72.06 | $77.95 | +8.2% | Mar 19, 2026 |
| SELL | $TPYP | Managed Portfolio Series Tortoise North American Pipeline Fund(ETF) | $1K-$15K | $42.30 | $42.50 | +0.5% | Mar 20, 2026 |
Connected Legislative Activity
10 signalsThese bills and contracts share tickers or sectors with this filing's trades.
Protecting Americans from Unsafe Drugs Act of 2026
The Protecting Americans from Unsafe Drugs Act of 2026 (HR7980) would expand FDA mandatory recall authority from controlled substances to all drugs, increasing structural operational risk and compliance costs for major pharmaceutical manufacturers. The bill is at an early legislative stage with a single Democratic sponsor, giving it low near-term passage probability. Market data shows the sector is already under pressure in April 2026 with JNJ, PFE, MRK, and AZN all down significantly over 30 days, but this bill is not yet being priced in as a material risk.
GAP Supply Act
The GAP Supply Act (HR7528) is an early-stage procedural bill with no funding authorization. It extends a regulatory timeline for compounding facilities during drug shortages but has near-zero near-term market impact. Current real market data shows $VTRS at $15.04 within its 52-week range of $8.19–$16.47, with a +11.32% 30-day gain reflecting broader market trends, not this bill.
DLA TROOP SUPPORT: $65.0M Department of Health and Human Services Contract
This $65.0 million contract for pharmaceuticals and related supplies, awarded to DLA Troop Support by the NIH, is likely to benefit major pharmaceutical companies as prime or sub-contractors, driven by ongoing federal healthcare needs. The award aligns with legislative support for healthcare services, suggesting a stable demand environment.
To require the Secretary of State, in consultation with the Secretary of Health and Human Services and other relevant departments and agencies, as appropriate, to formulate a strategy for the Federal Government to secure support from foreign countries, multilateral organizations, and other appropriate entities to facilitate the development and commercialization of qualified pandemic or epidemic products, and for other purposes.
The SUPER BUGS Act (HR7879) is a procedural bill with zero funding, no procurement mechanism, and no regulatory impact. It requires the State Department to develop a strategy for international pandemic product collaboration. Market impact is negligible — recent price moves in $PFE (-1.41% 7d), $MRNA (-7.27% 7d), $JNJ (+1.01% 7d), and $GILD (+0.18% 7d) reflect broader sector trends, not this legislation.
To amend title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary, and for other purposes.
HR8143 mandates Medicare Part D formularies give preferred placement to generic drugs and biosimilars with lower wholesale acquisition costs than brand-name reference products, effective January 1, 2027. This directly benefits pure-play generics manufacturers $VTRS and $TEVA by guaranteeing formulary access and restricting PBM utilization management. The bill is early stage (referred to committee) but has bipartisan sponsorship and clear structural impact on the Part D market.
Strengthening the Vaccines for Children Program Act of 2026
HR8425 is an early-stage authorization bill that expands VFC eligibility and mandates minimum Medicaid vaccine administration reimbursement rates, but it contains no funding appropriations. Market data shows no price reaction from PFE or MRNA following introduction. The bill is unlikely to generate material revenue changes for vaccine manufacturers without separate appropriations bills.
Most Favored Patient Act of 2026
HR7837, the Most Favored Patient Act of 2026, is a bearish catalyst for major pharmaceutical companies with high Medicare exposure. The bill proposes linking US Medicare drug prices to the lowest global price, directly threatening the US pricing premium that supports current industry margins. The bill is in early legislative stages but represents a credible structural threat to pharmaceutical pricing power.
To require the Secretary of Health and Human Services to establish a demonstration program to test mandatory coverage of treatment for wound care for epidermolysis bullosa under the Medicaid program.
HR7877 (Shane DiGiovanna Act) mandates a 2-year nationwide Medicaid demonstration program covering wound care and OTC drugs for epidermolysis bullosa. The bill is in early legislative stages (referred to committee, 5 cosponsors) with no explicit funding authorized. Market impact is minimal — the affected patient population is small (~3,000-5,000 individuals), and near-term passage is uncertain.
To amend the Public Health Service Act with respect to the Living Organ Donation Reimbursement Program.
HR7868, the 'Expanding Support for Living Donors Act of 2026,' is an early-stage bill authorizing up to $10,000 per donor for qualifying expenses in FY2027. Actual appropriations are required. The market reaction in diagnostic ($LH, $DGX) and device ($MDT, $SYK) stocks is currently driven by broader market trends — all four stocks are down 2-9% over the past 30 days — not by this bill's introduction. The legislative impact on revenue is negligible at this stage.
To amend title XVIII of the Social Security Act to ensure equitable payment for, and preserve Medicare beneficiary access to, cancer treatments under the Medicare hospital outpatient prospective payment system.
HR8032 (FAIC Act) is an early-stage bill requiring separate Medicare Part B payment for qualifying cancer drugs, eliminating a hospital incentive to avoid expensive branded oncology therapies. The bill protects $50B+ in oncology drug revenue for major pharma companies but faces a long legislative path through two committees. Current stock prices for affected tickers are near the bottom of their 52-week ranges, suggesting market pessimism is already priced in, creating asymmetric upside if the bill advances.
Other Filings by John Boozman
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.